Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| This was a record quarter and we noted continued strong demand for our consumables offering coming from high interest in supporting neurology |
| We continue to have a strong balance sheet with ample cash to fund growth |
| Non-GAAP gross margins improved 515 basis points versus fourth quarter prior year and cash used was $6.4 million, leaving us with over $320 million of liquidity on our balance sheet and in the strong position to deploy capital for growth investment |
| Over 80% of our revenue came from neurology where we continue to have a highly differentiated position |
| In '23, we built newly formulated assays, improving margins and manufacturability |
| Testing capacity in our Accelerator and manufacturing output improved by 50% and 300% respectively, each with new capacity to grow 3 fold from where they are today |
| These accomplishments over six quarters are the result of our team's focus, determination and strong operating discipline |
| The efforts have positioned us for better quality, higher throughput, faster innovation and are reflected in our financial performance for '23 with revenue growing 16%, non-GAAP gross margin improving over 1,300 basis points, all while we reduced cash burn by $40 million in 2023 as compared to '22 |
| We think the data for 217 is solid |
| But again, seeing really, really good demand on the Accelerator side |
| We continue to see accelerators be really strong and consumables also come out pretty strong |
| I want to say we are very proud of the talent density at Quanterix |
| It has also become clear that, identifying patients early in a disease cascade results in better patient outcomes |
| We continue to observe strong demand for our Accelerator services and this has been especially valuable to us in the current environment where tools have been capital constrained |
| The year-over-year margin expansion reflects the impact of our transformation efforts and favorable mix from increased sales of higher margin consumables and Accelerator services |
| Is that going to be enough do you think? And one for Vandana… Masoud Toloue We are very confident with the 217 results |
| Having said that, one thing I do want to add is we're somewhat fortunate that we have a strong balance sheet |
| It's a really unique offering and we're able to keep in touch with neurologists and really stay up to date on the latest of what's happening |
| As Masoud mentioned, the 2023 year end capped our corporate transformation and we've made significant execution progress over the six quarter program |
| There's now abundant evidence showing non-invasive testing methods using blood based biomarkers are equal to or better than invasive methods, and we believe they'll be the best solution for broadening access of therapies to patients |
| MolDX is obviously well respected and that read through was very important |
| From a -- your question on MolDX, we were super pleased that these multimarker algorithms are picked up |
| Developing this would be a significant breakthrough |
| Starting with Q4 of 2023, we hit record consumables production, delivering $17.5 million in revenue, contributing to $31.5 million of total revenue |
| And there, it's incredibly clear that, I mean, the data speaks for itself that the 217 test is superior to any other of the biomarkers out there |
| It's now really abundantly clear that 217 is a superior marker versus 181 |
| Our consumables revenue increased to $17.5 million or 56% compared to the fourth quarter of last year |
| Fourth quarter revenue from our Accelerator Lab was $5.6 million, an increase of 71% over the fourth quarter of 2022 |
| Our operating loss declined from $22 million in the fourth quarter of 2022 to $17 million in the fourth quarter of 2023 due to higher consumables and Accelerator sales and improved gross margins |
| Masoud Toloue So I think the partnership announcements we had a couple of days ago was super exciting |
| Statement |
|---|
| Instrument revenue was $3.3 million, a decline of 39% over the fourth quarter of 2022, similar to other tools companies and continuing the trends we saw in the second half of 2023 |
| I think the bigger question here is, with Leqembi and Donanemab expectations for the street have come down, they have settled |
| So still expecting to start the year with some amount of constraints on the instrument side |
| It's the super team who has made difficult and painful changes in the company |
| We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements |
| If you could just walk through how you're allocating diagnostic investments, specifically that'd be interesting to hear for the next two years? And then secondly, if you get -- just hypothetically, if you get any diagnostic revenue this year, would that come in at a negative gross margin? Vandana Sriram So on diagnostics, we had signaled earlier that we would spend a total of approximately $20 million between '24 and '25 |
| Diagnostics is a nascent area closely correlated to therapy adoption |
| So typically, when people look at things and you start to multiplex, you lose resolution as you add plexus |
| And then to your question on margin on diagnostics, we don't expect margin at this stage to be negative or overly dilutive to our portfolio but we just don't know enough about it right now |
| And consistent with our comments on revenue, it is premature to provide a cash flow breakeven point for diagnostics |
| And at this time, it is premature to provide guidance |
| So there might be some amount of choppiness in that first quarter as we get through that |
Please consider a small donation if you think this website provides you with relevant information